What is plasmablastic myeloma?
Plasmablastic myeloma is a rare and aggressive neoplasm presenting with overlapping features of multiple myeloma and non-Hodgkin’s lymphoma. There is no consensus on the management of plasmablastic myeloma.
How is plasmablastic myeloma treated?
Plasmablastic myeloma, regardless of its extensiveness or localisation, should be treated as high-risk myeloma [4]. Autologous stem cell transplantation is the standard of care for young high-risk multiple myeloma patients who respond to conventional myeloma chemotherapy [4-6].
What is plasmablastic neoplasm?
Plasmablastic lymphoma is an aggressive neoplasm that shares many cytomorphologic and immunophenotypic features with plasmablastic plasma cell myeloma. However, plasmablastic lymphoma is listed in the World Health Organization (WHO) classification as a variant of diffuse large B-cell lymphoma.
What is Plasmablastic morphology?
Plasmablastic morphology was considered to be present (plasmablastic myeloma) when 2% or more plasmablasts were present in the plasma-cell population. Results: Patients underwent transplantation 5 to 88 months (median, 20 months) after the initial diagnosis of myeloma.
What causes Plasmablastic lymphoma?
Plasmablastic lymphoma (PBL) is an aggressive subtype of non-Hodgkin’s lymphoma (NHL), which frequently arises in the oral cavity of human immunodeficiency virus (HIV) infected patients.
What is the survival rate of Plasmablastic lymphoma?
Plasmablastic lymphoma is an aggressive lymphoma with overall survival (OS) ranging from 7 to 62 months, according to small retrospective studies. It is associated with HIV infection in 50% to 69% of patients.
Can Plasmablastic lymphoma be cured?
Plasmablastic Lymphoma Is Curable The HAART Era. A 10 Year Retrospective By The AIDS Malignancy Consortium (AMC) | Blood | American Society of Hematology.
What does Plasmablastic mean?
In immunology, a “plasmablast” refers to a short-lived differentiation stage between a post germinal centre B-cell and a mature plasma cell. Plasmablasts retain a proliferative capability together with an almost fully mature plasma cell phenotype [1].
